Novartis Denied EU Panel Nod for Serelaxin Heart Drug Bloomberg Novartis AG (NOVN) failed to win backing from a European advisory panel for its Serelaxin treatment for acute heart failure, a product that had potential to garner as much as $1 billion in annual sales. Novartis will ask for conditional approval of the ... |
